SCHEMBL5669337

SCHEMBL5669337

[c]1nc2c(-c3nnn[nH]3)cccc2[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4988840 0.79 METAP2 (0.30)
SCHEMBL4623912 0.77 METAP2 (0.35)
SCHEMBL3226179 0.75 KDR (0.35)
SCHEMBL9590371 0.74 MGAM (0.40)
SCHEMBL434158 0.73 METAP2 (0.43)
SCHEMBL12615990 0.72 ALDH1A1 (0.38)
SCHEMBL5512822 0.71
SCHEMBL4190285 0.71 CSNK1A1 (0.42)
SCHEMBL352751 0.71
SCHEMBL9323558 0.70 PIK3CD (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0960108-B1 MATRIX METALLOPROTEINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2004-10-27 EP claimed
EP-0115997-A2 Derivatives of omega mercaptopropanamides, and their homologues, process for their preparation, their use as medicines, compositions containing them and intermediates obtained ROUSSEL-UCLAF (FR) 1984-08-15 EP claimed
EP-1653968-A4 METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS SYNTA PHARMACEUTICALS CORP (US) 2006-09-06 EP disclosed
EP-1653968-A2 METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS Synta Pharmaceuticals Corporation (US) 2006-05-10 EP disclosed
WO-2005009954-A2 METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS SYNTA PHARMACEUTICALS, CORP. (US) 2005-02-03 WO disclosed
EP-0960108-B1 MATRIX METALLOPROTEINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2004-10-27 EP disclosed
EP-0267565-A1 One-step process for preparing mixed substituted 1,2-diacyl-sn-glycero-3-phosphocholines Hafslund Nycomed Pharma Aktiengesellschaft (AT) 1988-05-18 EP disclosed